Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects

The demethylating agent 5-azacytidine (AZA) has proven its efficacy in the treatment of myelodysplastic syndrome and acute myeloid leukemia. In addition, AZA can demethylate FOXP3 intron 1 (FOXP3i1) leading to the generation of regulatory T cells (Treg). Here, we investigated the impact of AZA on xe...

Full description

Bibliographic Details
Main Authors: Grégory Ehx, Gilles Fransolet, Laurence de Leval, Stéphanie D'Hondt, Sophie Lucas, Muriel Hannon, Loïc Delens, Sophie Dubois, Pierre Drion, Yves Beguin, Stéphanie Humblet-Baron, Frédéric Baron
Format: Article
Language:English
Published: Taylor & Francis Group 2017-05-01
Series:OncoImmunology
Subjects:
azacytidine
graft-vs.-host disease
graft-vs.-leukemia effect
nod-scid il-2rγnull
regulatory t cells
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1314425

Internet

http://dx.doi.org/10.1080/2162402X.2017.1314425

Similar Items